Multicompartmental Analysis of [11C]-Carfentanil Binding to Opiate Receptors in Humans Measured by Positron Emission Tomography

[11C]-Carfentanil is a high affinity opiate agonist that can be used to localize mu opiate receptors in humans by positron emission tomography (PET). A four-compartment model was used to obtain quantitative estimates of rate constants for receptor association and dissociation. PET studies were performed in five normal subjects in the absence and presence of 1 mg/kg naloxone. Arterial plasma concentration of [11C]-carfentanil and its labeled metabolites were determined during each PET study. The value of k3/k4 = Bmax/kd was determined for each subject in the presence and absence of naloxone. There was a significant reduction in the value of k3/k4 from 3.4 ± 0.92 to 0.26 ± 0.13 in the thalamus (p < 0.01) and from 1.8 ± 0.33 to 0.16 ± 0.065 in the frontal cortex (p < 0.001). Mean values of frontal cortex/occipital cortex and thalamus/occipital cortex ratios were determined for the interval 35–70 min after injection when receptor binding is high relative to nonspecific binding. The relationship between the measured region/occipital cortex values and the corresponding values of k3/k4 in the presence and absence of naloxone was: regions/occipital cortex = 0.95 + 0.74 (k3/k4) with r = 0.98 (n = 20). Simulation studies also demonstrated a linear relationship between the thalamus/occipital cortex or frontal cortex/occipital cortex ratio and k3/k4 for less than twofold increases or decreases in k3/k4. Simulation studies in which thalamic blood flow was varied demonstrated no significant effect on the region/occipital cortex ratio at 35–70 min for a twofold increase or fourfold decrease in blood flow. Therefore, the region/occipital cortex ratio can be used to quantitate changes in k3/k4 when tracer kinetic modeling is not feasible.

[1]  M E Phelps,et al.  Performance evaluation of a positron tomograph designed for brain imaging. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  E. J. Simon,et al.  Selective changes in mu, delta and kappa opioid receptor binding in certain limbic regions of the brain in Alzheimer's disease patients. , 1987, Brain research.

[3]  E. J. Simon,et al.  Selective changes in μ, δ and ϰ opioid receptor binding in certain limbic regions of the brain in Alzheimer's disease patients , 1987, Brain Research.

[4]  M. Kuhar,et al.  Distribution and physiological significance of opioid receptors in the brain. , 1983, British medical bulletin.

[5]  L. Eriksson,et al.  Imaging of [11C]-labelled Ro 15-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography. , 1985, Journal of psychiatric research.

[6]  M. Reivich,et al.  THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1 , 1977, Journal of neurochemistry.

[7]  C. D. Arnett,et al.  Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients , 1988, Biological Psychiatry.

[8]  A. Herz,et al.  Opiate receptor binding sites in human brain , 1982, Brain Research.

[9]  J. Frost Imaging neuronal biochemistry by emission computed tomography: focus on neuroreceptors , 1986 .

[10]  S H Snyder,et al.  The opiate receptor. , 1975, Neurosciences Research Program bulletin.

[11]  G. Sedvall,et al.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.

[12]  J. Baron,et al.  In vivo quantitative imaging of dopamine receptors in human brain using positron emission tomography and [76Br]bromospiperone. , 1985, European journal of pharmacology.

[13]  A. Gjedde,et al.  Quantification of Neuroreceptors in the Living Human Brain. I. Irreversible Binding of Ligands , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  J S Fowler,et al.  Kinetic Modeling of Receptor‐Ligand Binding Applied to Positron Emission Tomographic Studies with Neuroleptic Tracers , 1987, Journal of neurochemistry.

[15]  L. Iversen,et al.  Opiate and neuroleptic receptor alterations in human schizophrenic brain tissue. , 1980, Advances in biochemical psychopharmacology.

[16]  K A Frey,et al.  Quantitative in vivo receptor binding III: Tracer kinetic modeling of muscarinic cholinergic receptor binding. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Dean F. Wong,et al.  Imaging Opiate Receptors in the Human Brain by Positron Tomography , 1985, Journal of computer assisted tomography.

[18]  C. Pert,et al.  In vivo autoradiography: Visualization of stress-induced changes in opiate receptor occupancy in the rat brain , 1984, Brain Research.

[19]  C. Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  E. H. Twizell The mathematical modeling of metabolic and endocrine systems: E.R. Carson, C. Cobelli and L. Finkelstein John Wiley and Sons, Chichester, Sussex, UK, 394 pp., £45.15, 1983 , 1984 .

[21]  K. B. Larson,et al.  Strategies for in vivo Measurement of Receptor Binding Using Positron Emission Tomography , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  S. Snyder,et al.  Imaging benzodiazepine receptors in man with [11C]suriclone by positron emission tomography. , 1986, European journal of pharmacology.

[23]  Jonathan M. Links,et al.  Imaging dopamine receptors in the human brain by positron tomography , 1983 .

[24]  J M Links,et al.  Quantification of Neuroreceptors in the Living Human Brain. II. Inhibition Studies of Receptor Density and Affinity , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[25]  H. Frenk Pro- and anticonvulsant actions of morphine and the endogenous opioids: Involvement and interactions of multiple opiate and non-opiate systems , 1983, Brain Research Reviews.

[26]  B. Zeeberg,et al.  Quantification of Human Caudate D2 Dopamine Receptor Density with Positron Emission Tomography: A Review of the Model , 1987, IEEE Transactions on Medical Imaging.

[27]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[28]  E. Hoffman,et al.  Quantitation in Positron Emission Computed Tomography: 1. Effect of Object Size , 1979, Journal of computer assisted tomography.

[29]  Alan A. Wilson,et al.  Mu‐opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy , 1988, Annals of neurology.

[30]  Henry N. Wagner,et al.  Kinetics of binding to opiate receptors in vivo predicted from in vitro parameters , 1984, Brain Research.

[31]  Albert Gjedde,et al.  Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: A re-examination , 1982, Brain Research Reviews.

[32]  J. Links,et al.  Imaging dopamine receptors in the human brain by positron tomography. , 1984, Science.